Getinge AB (publ) (GNGBF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GNGBF steht fuer Getinge AB (publ), ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 50/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026Getinge AB (publ) (GNGBF) Gesundheitswesen & Pipeline-Uebersicht
Getinge AB (publ) is a global provider of medical technology, offering solutions for operating rooms, intensive care units, and sterilization departments. With a diverse portfolio spanning acute care, life science, and surgical workflows, Getinge serves healthcare providers across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, maintaining a significant presence in the medical device industry.
Investmentthese
Getinge AB (publ) presents a compelling investment case based on its established market position and diverse product portfolio within the healthcare sector. With a current P/E ratio of 22.79 and a dividend yield of 2.43%, the company demonstrates financial stability. Growth catalysts include expanding its presence in emerging markets and continuous innovation in its core product segments. The company's focus on acute care therapies, life science solutions, and surgical workflows positions it to capitalize on increasing healthcare spending and technological advancements. However, potential risks include regulatory hurdles and competition from other medical device manufacturers. The company's gross margin of 45.9% and profit margin of 6.5% indicate a solid foundation for future growth.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $5.90B reflects Getinge's significant presence in the medical device industry.
- P/E Ratio of 22.79 indicates a valuation in line with industry peers.
- Gross Margin of 45.9% demonstrates efficient cost management and pricing strategies.
- Dividend Yield of 2.43% provides a steady return for investors.
- Beta of 0.88 suggests lower volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Strong global presence and distribution network.
- Diverse product portfolio across multiple healthcare segments.
- Established brand reputation and customer loyalty.
- Focus on innovation and technological advancements.
Schwaechen
- Exposure to regulatory risks and compliance requirements.
- Dependence on healthcare spending and economic conditions.
- Competition from larger medical device manufacturers.
- Potential for product recalls and liability claims.
Katalysatoren
- Ongoing: Expansion of product portfolio through research and development.
- Ongoing: Increasing demand for healthcare solutions in emerging markets.
- Ongoing: Strategic partnerships and acquisitions to expand market reach.
- Upcoming: Potential regulatory approvals for new medical devices.
- Upcoming: Launch of innovative surgical workflow solutions in Q4 2026.
Risiken
- Potential: Changes in healthcare regulations and reimbursement policies.
- Potential: Economic downturns and reduced healthcare spending.
- Ongoing: Increasing competition from established and emerging players.
- Potential: Product recalls and liability claims.
- Ongoing: Fluctuations in currency exchange rates.
Wachstumschancen
- Growth opportunity 1: Expansion in Emerging Markets: Getinge has the opportunity to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where healthcare spending is rapidly increasing. By tailoring its product offerings to meet the specific needs of these markets, Getinge can capitalize on the growing demand for advanced medical technologies. This expansion could contribute significantly to revenue growth over the next 3-5 years, with the global medical device market projected to reach $600 billion by 2025.
- Growth opportunity 2: Innovation in Surgical Workflows: Getinge can further enhance its surgical workflow solutions by integrating advanced technologies such as robotics and artificial intelligence. This would improve the efficiency and precision of surgical procedures, leading to better patient outcomes and increased demand for Getinge's products. The market for surgical robotics is expected to reach $12.6 billion by 2025, presenting a substantial growth opportunity for Getinge.
- Growth opportunity 3: Focus on Infection Control Solutions: With increasing concerns about hospital-acquired infections, Getinge can capitalize on the growing demand for advanced infection control solutions. By developing innovative sterilization and disinfection technologies, Getinge can help healthcare providers reduce the risk of infections and improve patient safety. The global infection control market is projected to reach $25 billion by 2027, offering a significant growth opportunity for Getinge.
- Growth opportunity 4: Strengthening the Life Science Segment: Getinge's Life Science segment can benefit from the increasing demand for bioprocessing solutions in the pharmaceutical and biotechnology industries. By expanding its portfolio of bioreactors, bioprocess control systems, and bioprocess software, Getinge can support the development and manufacturing of new drugs and therapies. The global bioprocessing market is expected to reach $35 billion by 2028, presenting a substantial growth opportunity for Getinge.
- Growth opportunity 5: Strategic Acquisitions and Partnerships: Getinge can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or entering into partnerships with leading healthcare providers, Getinge can strengthen its competitive position and accelerate its growth. This strategy can provide access to new markets and technologies, enhancing Getinge's long-term growth prospects.
Chancen
- Expansion in emerging markets with growing healthcare demand.
- Development of new products and solutions to address unmet needs.
- Strategic acquisitions and partnerships to expand market reach.
- Integration of advanced technologies such as AI and robotics.
Risiken
- Increasing competition from established and emerging players.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and reduced healthcare spending.
- Disruptive technologies and new market entrants.
Wettbewerbsvorteile
- Established brand reputation in the medical device industry.
- Diverse product portfolio across multiple healthcare segments.
- Global distribution network providing access to a wide customer base.
- Strong focus on innovation and technological advancements.
Ueber GNGBF
Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a leading global provider of medical technology. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products and solutions for intensive care units, including advanced monitoring systems, anesthesia machines, and mechanical ventilation products. The Life Science segment provides solutions for sterile transfer, bioprocess control, and sterilization within the pharmaceutical and biotechnology industries. The Surgical Workflows segment focuses on optimizing operating room efficiency with products such as operating tables, surgical lights, and integrated OR management systems. Getinge's comprehensive portfolio includes sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems. The company also offers practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, and a range of surgical solutions. Getinge distributes its products through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, serving a global customer base.
Was das Unternehmen tut
- Provides equipment for operating rooms.
- Offers solutions for intensive-care units.
- Supplies sterilization departments with necessary equipment.
- Develops and markets sterile transfer systems.
- Creates bioprocess control systems for the life science industry.
- Offers surgical assist systems and related solutions.
- Provides solutions for vascular and cardiothoracic surgery.
Geschaeftsmodell
- Develops and manufactures medical devices and equipment.
- Sells products directly through proprietary sales companies.
- Utilizes agents and distributors for broader market reach.
- Provides after-sales service and support for its products.
Branchenkontext
Getinge AB (publ) operates within the global medical device industry, a sector characterized by continuous innovation and increasing demand driven by an aging population and rising healthcare expenditures. The industry is highly competitive, with key players focusing on technological advancements and geographic expansion. Getinge's focus on acute care therapies, life science solutions, and surgical workflows aligns with major market trends, including the growing demand for minimally invasive surgical procedures and advanced sterilization technologies. The company's global presence allows it to capitalize on growth opportunities in both developed and emerging markets.
Wichtige Kunden
- Hospitals and healthcare facilities.
- Pharmaceutical and biotechnology companies.
- Research institutions.
- Sterilization departments.
Finanzdaten
Chart & Info
Getinge AB (publ) (GNGBF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GNGBF.
Kursziele
Wall-Street-Kurszielanalyse fuer GNGBF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von GNGBF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Aktuelle Nachrichten
Fuehrung: Mattias Perjos
President & CEO
Mattias Perjos serves as the President and CEO of Getinge AB (publ). His career includes leadership roles in various technology and healthcare companies. He has a strong background in strategic management and business development. Prior to joining Getinge, Perjos held key positions at Coesia Group and Sandvik, gaining experience in international business and operational excellence. His expertise spans across multiple industries, providing him with a diverse perspective on business challenges and opportunities.
Erfolgsbilanz: Under Mattias Perjos' leadership, Getinge has focused on strengthening its core business segments and expanding its global presence. He has overseen the implementation of strategic initiatives aimed at improving operational efficiency and driving innovation. Key achievements include the launch of new products and solutions, as well as the expansion of Getinge's service offerings. Perjos has also emphasized sustainability and corporate responsibility, aligning Getinge's business practices with environmental and social goals.
GNGBF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Getinge AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet higher listing standards. Investors should exercise significant caution when considering investments in OTC Other securities due to the increased risks associated with limited information and potential for fraud or manipulation.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited Financial Disclosure: The lack of readily available and reliable financial information increases the risk of investing in GNGBF.
- Low Liquidity: The low trading volume and wide bid-ask spread can make it difficult to buy or sell shares at a fair price.
- Potential for Fraud or Manipulation: The OTC market is more susceptible to fraudulent schemes and market manipulation due to the lower regulatory oversight.
- Delisting Risk: GNGBF could be delisted from the OTC market if it fails to meet the minimum listing requirements or comply with regulatory standards.
- Information Asymmetry: The limited information available to investors can create an uneven playing field, where insiders have an advantage over outside investors.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's filings with regulatory agencies.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Check for any legal or regulatory actions against the company.
- Established Operations: Getinge AB (publ) has been in operation since 1904, indicating a long-standing presence in the medical device industry.
- Global Presence: The company has a global distribution network and serves customers in multiple regions.
- Diverse Product Portfolio: Getinge offers a wide range of products and solutions across various healthcare segments.
- Publicly Traded: While traded on the OTC market, the company is a publicly traded entity, subject to some level of regulatory oversight.
Haeufige Fragen zu GNGBF
What are the key factors to evaluate for GNGBF?
Getinge AB (publ) (GNGBF) currently holds an AI score of 50/100, indicating moderate score. Key strength: Strong global presence and distribution network.. Primary risk to monitor: Potential: Changes in healthcare regulations and reimbursement policies.. This is not financial advice.
How frequently does GNGBF data refresh on this page?
GNGBF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNGBF's recent stock price performance?
Recent price movement in Getinge AB (publ) (GNGBF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong global presence and distribution network.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNGBF overvalued or undervalued right now?
Determining whether Getinge AB (publ) (GNGBF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNGBF?
Before investing in Getinge AB (publ) (GNGBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNGBF to a portfolio?
Potential reasons to consider Getinge AB (publ) (GNGBF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong global presence and distribution network.. Additionally: Diverse product portfolio across multiple healthcare segments.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of GNGBF?
Yes, most major brokerages offer fractional shares of Getinge AB (publ) (GNGBF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GNGBF's earnings and financial reports?
Getinge AB (publ) (GNGBF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GNGBF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- AI analysis pending may provide further insights.
- OTC market data may have limited accuracy.